21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender

Carlos Moran; Ricardo Azziz

doi:10.1055/s-2003-43307

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2003; 21(3): 295-300
DOI: 10.1055/s-2003-43307

21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender

Carlos Moran¹ , Ricardo Azziz²

¹Health Research Council, Mexican Institute of Social Security, Mexico City, Mexico
²Division of Reproductive Biology and Endocrinology, Department of Obstetrics and Gynecology, and Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama

Abstract

ABSTRACT

Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

KEYWORDS

Polycystic ovary syndrome - adrenal hyperplasia - hyperandrogenism

Full Text

References

REFERENCES

1 Zawadzki J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic Ovary Syndrome Boston: Blackwell Scientific 1992: 377-384
2 Azziz R, Boots L R, Parker Jr R C, Bradley Jr E, Zacur H A. 11β-Hydroxylase deficiency in hyperandrogenism. Fertil Steril . 1991; 55 733-741
3 Azziz R, Bradley Jr L E, Potter H D, Boots L R. 3β-Hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am J Obstet Gynecol . 1993; 168 889-895
4 Joehrer K, Geley S, Strasser-Wozak E MC. et al . CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11β-hydroxylase deficiency. Hum Mol Genet . 1997; 6 1829-1834
5 Moran C, Potter H D, Reyna R, Boots L R, Azziz R. Prevalence of 3β-hydroxysteroid dehydrogenase deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Am J Obstet Gynecol . 1999; 181 596-600
6 Azziz R, Hincapie L A, Knochenhauer E S, Dewailly D, Fox L, Boots L R. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril . 1999; 72 915-925
7 Moran C, Azziz R, Carmina E. et al . 21-Hydroxylase- deficient nonclassic adrenal hyperplasia is a progressive disorder. Am J Obstet Gynecol . 2000; 183 1468-1474
8 Speiser P W, Knochenhauer E S, Dewailly D, Fruzzetti F, Marcondes J AM, Azziz R. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype. Mol Genet Metab . 2000; 71 527-534
9 Bachega T S S A, Billerbeck A EC, Marcondes J AM, Madureira G, Arnhold I JP, Mendonca B B. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) . 2000; 52 601-607
10 Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab . 1994; 78 810-815
11 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab . 1998; 83 3078-3082
12 Asuncion M, Calvo R M, San Millan L J, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab . 2000; 85 2434-2438
13 Moran C, Tapia M C, Hernandez E, Vazquez G, Garcia-Hernandez E, Bermudez J A. Etiological review of hirsutism in 250 patients. Arch Med Res . 1994; 25 311-314
14 Romaguera J, Moran C, Diaz-Montes T P, Hines G A, Cruz R I, Azziz R. Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico. Fertil Steril . 2000; 74 59-62
15 Sanchez L A, Knochenhauer E S, Gatlin R, Moran C, Azziz R. Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients. The Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL, October 20-25, 2001 (Abstract O-294). Fertil Steril . 2001; 76 S111
16 Speiser P W, Dupont B, Rubinstein P, Piazza A, Kastelan A, New M I. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet . 1985; 37 650-657
17 Chetkowski R J, DeFazio J, Shamonki I, Judd H L, Chang R J. The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. J Clin Endocrinol Metab . 1984; 58 595-598
18 Azziz R, Zacur H A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab . 1989; 69 577-584
19 Kuttenn F, Couillin P, Girard F. et al . Late-onset adrenal hyperplasia in hirsutism. N Engl J Med . 1985; 313 224-231
20 Motta P, Catania A, Airaghi L, Mangone I, Cantalamessa L, Zanussi C. Prevalence of late-onset adrenal hyperplasia in postmenarchal hirsutism. J Endocrinol Invest . 1988; 11 675-678
21 Innanen V T, Vale J M. Assessment of the one hour adrenocorticotrophic hormone test in the diagnosis of attenuated 21-hydroxylase deficiency. J Clin Pathol . 1990; 43 493-495
22 Mithal A, Ammini A C, Godbole M M. et al . Late-onset adrenal hyperplasia in north Indian hirsute women. Horm Res . 1988; 30 1-4
23 Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A, Roslër A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. N Engl J Med . 1990; 323 855-863
24 Khandekar S, Lata V, Dash R J. Screening for late onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Indian J Med Res . 1990; 92 79-82
25 Arnaout M A. Late-onset congenital adrenal hyperplasia in women with hirsutism. Eur J Clin Invest . 1992; 22 651-658
26 Goldzieher J W, Green J A. The polycystic ovary I: clinical and histologic features. J Clin Endocrinol Metab . 1962; 22 325-338
27 Conway G S, Honour J W, Jacobs H S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) . 1989; 30 459-470
28 Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) . 1989; 31 87-120
29 Dewailly D, Vantyghem-Haudiquet M C, Sainsard C. et al . Clinical and biological phenotypes in late-onset 21 hydroxylase deficiency. J Clin Endocrinol Metab . 1986; 63 418-423
30 Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?. Am J Obstet Gynecol . 1992; 167 1807-1812
31 Levin J H, Carmina E, Lobo R A. Is the inappropriate gonadotropin secretion of patients with the polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?. Fertil Steril . 1991; 56 635-640
32 Moran C, Knochenhauer E, Boots L R, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril . 1999; 71 671-674
33 Huerta R, Dewailly D, Decanter C, Knochenhauer E S, Boots L R, Azziz R. 11β-Hydroxyandrostenedione and Δ⁵-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase deficient nonclassic adrenal hyperplasia. Fertil Steril . 1999; 72 996-1000
34 New M I, Lorenzen F, Lerner A J. et al . Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab . 1983; 57 320-326
35 Auchus R J, Lee T C, Miller W L. Cytochrome b₅ augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem . 1998; 273 3158-3165
36 Azziz R, Rafi A, Smith B R, Bradley Jr L E, Zacur H A. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism. J Clin Endocrinol Metab . 1990; 70 431-436
37 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes . 1989; 38 1165-1174
38 Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab . 1998; 83 2694-2698
39 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab . 1999; 84 165-169
40 Talbott E, Clerici A, Berga S L. et al . Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol . 1998; 51 415-422
41 Speiser P W, Serrat J, New M I, Gertner J M. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992; 75 1421-1424
42 Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril . 2001; 75 53-58
43 Miller W L. Molecular biology of steroid hormone synthesis. Endocr Rev . 1988; 9 295-318
44 Miller W L. Genetics, diagnosis and management of 21-hydroxylase deficiency. J Clin Endocrinol Metab . 1994; 78 241-246